EPISODE · Nov 19, 2024 · 29 MIN
Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals
from BioCentury This Week · host BioCentury
Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way.BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years ago — help make the case for introducing new therapies earlier in the course of treatment, and the recent bolus of West-East deals, including two around anti-PD-(L)1 x VEGF bispecifics: BioNTech's acquisition of Biotheus, and Merck's licensing of global rights to a LaNova asset.View full story: https://www.biocentury.com/article/65423300:00 - Introduction01:12 - RFK Jr. & HHS13:15 - Blenrep's Comback19:25 - China DealsTo submit a question to BioCentury’s editors, email the BioCentury This Week team at [email protected] us by sending a text
What this episode covers
Giving RFK Jr. control of HHS would be disastrous, argues Washington Editor Steve Usdin on the latest BioCentury This Week podcast. Expanding on his Editor’s Commentary, Usdin explains why Kennedy would be an unmitigated disaster for FDA, NIH and CMS, for biopharmas and for patients. He calls on biopharma leaders to speak out and affirm basic truths, even if it puts them in harm’s way. BioCentury’s editors also discuss why new data for GSK's Blenrep — an oncology therapy withdrawn two years a...
NOW PLAYING
Ep. 265 - RFK Jr. & HHS, Blenrep's Comeback, China Deals
No transcript for this episode yet
Similar Episodes
Mar 26, 2026 ·1m
Mar 3, 2026 ·44m
Feb 21, 2026 ·30m
Jan 2, 2026 ·47m